II型糖尿病及口服降糖药物综述  

Tyve 2 Diabetes and Oral Antiyperglycemic Drugs

作　　者：孙广田 李娟娟 

机构地区：[1]阜阳卫生学校,安徽阜阳236000

出　　处：《医药前沿》2015年第11期7-9,共3页Journal of Frontiers of Medicine

摘　　要：Ⅱ型糖尿病主要是由于环境或者遗传引起的内源性疾病，因其高昂的治疗费用及难于根治而成为摆在全世界卫生组织和各政府面前的一道难题。Ⅱ型糖尿病的治疗已经乏力几十年了，至今还没有一个安全的单独治疗药物的出现。现有的口服降血糖药物大致可以分为磺酰脲类药物、双胍类药物、葡萄糖苷酶、氯茴苯酸类药物，DPP-4抑制剂和噻唑烷二酮类药物，但这些药物的安全性和疗效值得关注。在这篇文章里，我们分析了这六种药物的优缺点，讨论几种治疗Ⅱ型糖尿病新型药物的趋势。Type II diabetes is a heterogeneous disease where environment and genetics are important Factors for the expression of the disease.The high cost for treating complications of diabetes is a burden for public health systems and governments worldwide. Type II diabeteshas been causing debilitation worldwide for many decades, and a single drug that safely treats the disease has not been discoverecLSulfonylureas, biguanides, a-glucosidase, meglifinides, DPP-4 inhibitors and thiazolidinediones are among the classes of oral hypoglycemicdrugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs. In this article we present the pros and cons of the six classes and discuss some of the latest advances towards the development of new drugs for the treatment of Type II diabetes.

关 键 词：Ⅱ型糖尿病 口服降糖药物 胰岛素敏感药物 过氧化物酶体增殖物激活受体 DPP-4抑制剂 

分 类 号：R587.1[医药卫生—内分泌]